-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Supernus Pharmaceuticals, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2017 to Q1 2024.
- Supernus Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$5.48M, a 1160% decline year-over-year.
- Supernus Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$26.3M, a 427% decline from 2021.
- Supernus Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was -$4.99M, a 979% decline from 2020.
- Supernus Pharmaceuticals, Inc. annual Deferred Income Tax Expense (Benefit) for 2020 was $568K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)